Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer supporting GARFIELD, an atrial fibrillation registry

This article was originally published in Scrip

Executive Summary

A research grant from Bayer Schering Pharma is supporting GARFIELD (the global anticoagulant registry in the field), the first-ever global atrial fibrillation registry. It will follow, for six years, 50,000 patients from 32 countries who are newly diagnosed with atrial fibrillation. GARFIELD is the first prospective registry in the condition; clinical sites will be selected at random to avoid selection bias, and patients included whether or not they receive anticoagulant therapy. The study is being conducted by the Thrombosis Research Institute, which is affiliated with Queen Mary University of London.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts